Kaiser Permanente cancels plans to build new $900M headquarters

Kaiser Permanente, the nonprofit health system based in California, has canceled its plans to build new headquarters expected to cost $900 million.

The news was reported by the San Francisco Chronicle. The project was expected to be a significant boost to the local economy in Oakland, where the headquarters was set to be built. The new headquarters would have housed more than 7,000 employees, which are currently spread across seven offices in East Bay.

The cancellation comes at a time when the economy has suffered a major blow from the new coronavirus, COVID-19, which has put nearly one in five workers out of work as efforts to contain the spread of the virus shut down businesses.

However, Kaiser did not state the cancellation of the project is because of COVID-19 specifically.

"Delays and increasing costs related to this project caused us to re-examine the feasibility and focus on renovating our current buildings. The decision is not related to COVID-19," Kaiser told Health Exec. "Kaiser Permanente appreciates the hard work by the developer and its team on the 2100 Telegraph Avenue project. We wish them well with the project and look forward to welcoming new neighbors to downtown Oakland when it’s completed."

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.